BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
Status:
Terminated
Trial end date:
2012-01-06
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies, such as BCG, may stimulate the immune system in different
ways and stop tumor cells from growing. Gefitinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Giving BCG together with gefitinib may
kill more tumor cells. It is not yet known whether BCG is more effective with or without
gefitinib in treating bladder cancer.
PURPOSE: This randomized phase III trial is studying BCG and gefitinib to see how well they
work compared to BCG alone in treating patients with high-risk bladder cancer.